Jennifer L. Fisher

Signature reversion of three disease-associated gene signatures prioritizes cancer drug repurposing candidates

The paper identifies drug repurposing candidates for low-survival cancers by prioritizing drugs that reverse disease-associated gene signatures using three methods.

Inferring chromosomal instability from copy number aberrations as a measure of chromosomal instability across human cancers

The paper compares six copy number-based chromosomal instability (CIN) metrics across 33 TCGA cancer datasets to assess their correlation with tumor type, clinical characteristics, and patient sex.

Evaluating cancer cell line and patient-derived xenograft recapitulation of tumor and non-diseasedtissue gene expression profiles in silico

The paper evaluates how well cancer cell lines and PDX models recapitulate human tumor and non-diseased tissue gene expression profiles using in silico analysis.

Sex-biased gene expression and gene-regulatory networks of sex-biased adverse event drug targets and drug metabolism genes

The paper identifies sex-biased adverse event drug targets and metabolism genes, showing their sex-specific gene expression and regulatory networks.

Prioritized polycystic kidney disease drug targets and repurposing candidates from pre-cystic and cystic mouse Pkd2 model gene expression reversion

The paper identifies drug targets and repurposing candidates for ADPKD by analyzing gene expression signatures from mouse Pkd2 models using signature reversion.